# Biodexa Pharmaceuticals Plc: overview

BDRX · Nasdaq · CIK 1643918 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bdrx.md) · [Financials](/companies/bdrx/financials.md) · [Filings](/companies/bdrx/filings.md) · [Insiders](/companies/bdrx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.55)](/filings/0001214659-25-005742.md) | [(0.02)](/filings/0001214659-26-003921.md) | [(0.00)](/filings/0001214659-26-003921.md) | [(0.00)](/filings/0001214659-26-003921.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL not reported.
- Net margin (net income / revenue). XBRL not reported.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bdrx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $43.1k | 14,809 |  | New +14,809 |
| [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $3.5k | 1,203 |  | New +1,203 |
| [Allied Private Wealth LLC](/funds/2132253.md) | 2026-06-30 | $1.3k | 489 |  | Not compared |
| [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $84 | 29 |  | Reduced −122 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $73 | 25 |  | New +25 |
| [Hilton Head Capital Partners, LLC](/funds/2109913.md) | 2026-06-30 | $17 | 6 |  | New +6 |
| [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $15 | 5 |  | New +5 |

## Recent filings

[All 731 filings](/companies/bdrx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 12:30 ET | [6-K](/filings/0001171843-26-006616.md) | Report of a foreign private issuer, period 2026-10-14 | 0001171843-26-006616 |
| 2026-10-08 | 20:03 ET | [6-K](/filings/0001214659-26-012706.md) | Report of a foreign private issuer, period 2026-10-08 | 0001214659-26-012706 |
| 2026-09-15 | 12:27 ET | [6-K](/filings/0001214659-26-011688.md) | Report of a foreign private issuer, period 2026-09-15 | 0001214659-26-011688 |
| 2026-09-11 | 20:49 ET | [6-K](/filings/0001214659-26-011630.md) | Report of a foreign private issuer, period 2026-06-30 | 0001214659-26-011630 |
| 2026-07-29 | 20:43 ET | [6-K](/filings/0001214659-26-009162.md) | Report of a foreign private issuer, period 2026-07-29 | 0001214659-26-009162 |
| 2026-07-09 | 20:15 ET | [6-K](/filings/0001214659-26-008398.md) | Report of a foreign private issuer, period 2026-07-09 | 0001214659-26-008398 |
| 2026-06-30 | 20:30 ET | [6-K](/filings/0001171843-26-004399.md) | Report of a foreign private issuer, period 2026-06-30 | 0001171843-26-004399 |
| 2026-06-30 | 13:19 ET | [6-K](/filings/0001214659-26-007903.md) | Report of a foreign private issuer, period 2026-06-30 | 0001214659-26-007903 |
| 2026-06-17 | 20:50 ET | [6-K](/filings/0001214659-26-007536.md) | Report of a foreign private issuer, period 2026-06-17 | 0001214659-26-007536 |
| 2026-05-14 | 20:00 ET | [6-K](/filings/0001214659-26-006195.md) | Report of a foreign private issuer, period 2026-05-14 | 0001214659-26-006195 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001214659-26-003921.md), filed Mar 27, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1643918
- Tickers: BDRX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: X0
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.